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The MONICA centres in Belfast, Lille, Strasbourg and Toulouse have taken part
in the WHO coordinated MONICA (MONItoring in CArdiovascular diseases)
Project since the early 1980s. In order to test the Project's main objective to
investigatethe relationships between 10 yeartrends in the major CVD riskfactors
(serum cholesterol, blood pressure and cigarette consumption) and 10 year
trends in incidence rates, the centres register coronary events and carry out risk
factor surveys. The registration of events validates a four-fold greater incidence
of ischaemic heart disease in Belfast than Toulouse, and the risk factor surveys
showthatthemajorriskfactors areidentical betweenthesetwocentres. Adietary
comparison also shows no important differences apart from a higher
polyunsaturated fat, wine, cheese, fruit and vegetable intake in Toulouse (See
Abstract 3).
Since 1988 a programmeofstudieshasbeen mountedinthefourcentres. Alarge
case-control study (ECTIM) completed its intake of 1,474 cases and controls in
1992 (See Abstract 4). In Belfastthe ECTIM Study has been extended to women
and into the families ofthe probands. PRIME, a cohort study began recruitment
in 1991 (See Abstract 22). This recruitment will be concluded in the autumn of
1993 with a total intake of 11,000 middle-aged males in Northern Ireland and
France; thereafter, there will be a 5 - 7 year follow-up. Intervention studies are
also planned within this research programme.
This major collaboration, in addition to the four MONICA centres, involves
several laboratories in Northern Ireland and France.
The two day meeting at Queen's University, held in conjunction with the Irish
Hyperlipidaemia Association, was attended by 50 visitors from France,
Switzerland, Spain, Scotland, England, Wales and the south of Ireland. It was
opened by Dr Ivan Gyarfas, Chief of Cardiovascular Disease in WHO, Geneva.
Key items presented and discussed were the deletion polymorphism ofthe ACE
gene which has been identified as a risk factor for myocardial infarction in the
ECTIM Study (See Abstract 9 and 19); the HVR48+ polymorphism of the
apolipoprotein B gene which carries a high odds ratio for myocardial infarction
inoverweightsubjectsinBelfastandFrance (SeeAbstract 12); andpolymorphisms
ofthe lipoprotein lipasegene (SeeAbstract 15) which alsoappearsto predispose
to myocardial infarction. The major lipid difference between the French and
Northern Irish populations is a lipid profile characterised by high levels of LpE:B
and Lp(a)B and low levels of LpA1 in Belfast (See Abstract 7).
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In conclusion, the contribution ofmolecular genetics totraditional epidemiology
is immense as we are beginning to understand how environmental risk factors
interact with the individual's genetic constitution.
Alun Evans
Professor of Epidemiology
Department of Epidemiology and Public Health
The Queen's University of Belfast.
HEART ATTACKS IN NORTHERN IRELAND
Evans A E', McMaster D2, McCrum E E', Kerr M McFl, O'Reilly D', McConville
M', Hall Al, Mathewson Z', Kee F', Patterson C C', Mcllmoyle E Ll.
'BelfastMONICA, NorthernIreland; 2DepartmentofMedicine, Queen'sUniversity
of Belfast.
The BelfastMONICA Project has been registering coronary heart disease events
as part of the WHO coordinated Project since 1983. The area covered is to the
eastoftheProvince (Belfast, Castlereagh, North DownandArds Health Districts)
withatotalpopulationof510,000persons. Despiteitspre-eminence inischaemic
heart disease mortality during the 1980s when it vied with Scotland for the
premier position in age-standardised rates for both men and women (40-69
years), over the decade 1980-90 statutory age-standardised IHD mortality data
showed a 30% decline in men and a 25% decline in women (40-69 years).
MONICA event registration data for males aged 25-64 years in Belfast showed
a peak in 1984 of 431/100,000, with a decline to 272/100,000 in 1990: the
corresponding rates in females were 137 and 100/100,000. Population surveys
took place in 1983-4, 1986-7 and 1991-2 and risk factor data were assembled.
Applying two multiple logistic function scoring systems (UK Heart Disease
Prevention Project - age, cigs, chol, systolic BPand BMI and the British Regional
Heart Study - age, cigs, chol, HDL-chol, mean BP and BMI), which estimate the
chance of developing heart disease over the subsequent 4-5 years, resulted in
trends which were broadly in agreement with the trends in incidence.
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HEART ATTACKS IN FRANCE: CORONARY MORTALITY AND
MORBIDITY, GEOGRAPHIC AND TEMPORAL TRENDS (1985-89)
Richard J LI, Arveiler D2, Cambou J-P3, Amouyel P4, Bingham Al, Montaye M,
Ruidavets J-B3, Schaffer p2.
1INSERMU258, Paris, France;2MONICABas-Rhin, Strasbourg, France; 3 MONICA
Haute-Garonne, Toulouse, France; 4 Institut Pasteur, Lille, France.
The three French MONICA centres are located in the areas ofToulouse (TOU),
Strasbourg (STRA) and Lille (LIL), respectively inthesouth, eastandnorthofthe
country. Theycoversimilarsamplesizepopulations (about500,000inhabitants,
aged35-64 years). Acutecoronaryeventsaremonitoredandclassifiedfollowing
the MONICA protocol but taking also into account medical diagnoses or death
certification. There were 11,310 coronary acute events (ALL) with 57,331
definite acute myocardial infarctions (AMI) and 3,004 coronary deaths (CD) for
the period 1985-89. Male cases made up 81% of ALL.
The first table gives age-standardized mean annual rates per 1000 for AMI, ALL
and CD. Except for AMI, rates are slightly lower in TOU, particularly in females.
MALES FEMALES
TOU STR LIL p TOU STR LIL p
AMI 1.82 2.13 1.73 <0.001 0.22 0.43 0.28 <0.001
ALL 3.53 4.10 3.91 <0.001 0.56 0.98 0.85 <0.001
CD 0.77 1.13 1.16 <0.001 0.13 0.26 0.22 <0.001
The second table gives age-standardized trends estimated from a logistic
regressionmodelandexpressedasa relativepercentagevariationofratesduring
the period (men only).
TOU p STR p LIL p
AMI -4 ns -13 <0.05 -25 <0.001
ALL +6 ns -6 ns -18 <0.001
CD -32 <0.001 -21 <0.02 -19 <0.05
In general, all rates are decreasing in LIL, but attack ratesforall events are stable
in TOU and STR. CD are strongly decreasing in all centres in agreement with
official death statistics. Coronary morbidity and mortality are not homogeneous
in France. Such a geographic and temporal variability merits discussion and
further research.
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PREVIOUS NUTRITIONAL STUDIES
Ruidavets J-BI, Evans A2, Arveiler D3, NuttensMC4, McCrum E E2, Richard J L5,
Bingham A5, Cambou J-p1.
I MONICA Haute-Garonne, Toulouse, France; 2 Belfast MONICA, Northern
Ireland; 3 MONICA Bas-Rhin, Strasbourg, France; 4 MONICA Lille, France,
5INSERM U 258, Paris, France.
Several hypotheses have been put forward to explain the differences in the
incidence ofCHD and mortality between France and North European countries.
The incidence is fourfold higher in Belfast than in the 3 French registers.
Conventional cardiovascular risk factors do not account for such differences.
PopulationsurveyscarriedoutwithintheframeworkofMONICAregistersandthe
ECTIM study reflect the absence of striking differences in conventional risk
factors between France and Northern Ireland. Specific regional nutritional habits
might account for the differences in the frequency of disease. The Belfast
MONICA Centre and the 3 French registers participated in a nutritional survey
(EURONUIT) carriedoutin a representative populationsample. Thecomparative
analysis of the results of the initial nutritional survey, which was carried out in
men aged 45-64 years in Belfast and in Toulouse, shows a higher consumption
of polyunsaturated fatty-acids in the Haute-Garonne (7.1% vs 4.6% of total
energy) with a higher P/S ratio (0.50 vs 0.30), a lower alcohol consumption in
Belfast (3.6% vs 6.4% oftotal energy) and a higher intake offruit and vegetables
inthe Haute-Garonne. ThevitaminC serumlevel found inmalesistwofoldhigher
in Haute-Garonne (Gey et al 1991) in accordance with the amount ofvegetable
intake. Nutritional behaviour differences seem to corroborate the hypothesis of
the protective role of unsaturated fat and vitamins (E and C) against IHD. The
predictive aspect of the different risk factors (lipoprotein profile, antioxidants)
highlighted by the MONICA population surveys must be investigated in the
frameworkofa prospectivestudy (PRIMEStudy) nowbeing carried outin Belfast
and in the 3 French MONICA Centres.
© The Ulster Medical Society, 1993.
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GENERAL DESIGN OF THE ECTIM STUDY
D Arveilerl, J-B Ruidavets2, G Luc3, A Evans 4,A Bingham5, V Meyer', B Haas',
F Cambien6.
' MONICA Bas-Rhin, Strasbourg, France; 2 MONICA Haute-Garonne, Toulouse,
France; 3 MONICA Lille, France; 4 Belfast MONICA, Northern Ireland; 5 INSERM
U258, Paris, France; 6 INSERM SC7, Paris, France.
The ECTIM Study is a multicentre case-control study set up to investigate the
large differences in ischaemic heart disease incidence and mortality between
centres taking part in the WHO MONICA Project: the three French Centres
(Strasbourg, Toulouse, Lille) andthe Northern Ireland Centre in Belfast. The aim
of the study is to compare the frequency of DNA polymorphisms in patients
having suffered an acute myocardial infarction (MI) and in controls, andto study
theassociation betweenthesepolymorphismsandvariousfactorsinvolvedinthe
metabolism of lipids and of clotting factors: 662 cases and 812 controls were
included between December 1988 and May 1992.
The cases and controls were men aged 25-64 years resident in the geographical
areas covered by the MONICA registers. Their family had to have settled in the
region for at least 2 generations. The cases were patients with a definite acuteMI
(MONICA Diagnostic Category 1), surviving 3 to 9 months afterthe acute event.
The controls were age-matched menfromthesame population asthe cases. The
participation rates were 60% in Belfast, 68% in Toulouse, 56% in Strasbourg and
55% in Lille.
The cases and the controls were interviewed in a standardised way in the four
centres, mostly by home visiting. The questionnaire for cases and controls
concerned personal and familial histories as well as exposure to potential
deleterious factors for the cardiovascular system (smoking habits, alcohol
consumption, blood pressure measurement, anthropometric measurements
etc). Furthermore, there was a specific questionnaire for controls, based on the
ROSEquestionnaire, andanotherforcaseswhichcollectedclinicaldataconceming
the acute event.
A blood sample was taken on fasting subjects for the setting up of a DNA bank,
a plasma bank, the measurement of lipid parameters and clotting factors. The
biological measurements were all centralised in specialised laboratories.
© The Ulster Medical Society, 1993.
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MEDICAL TREATMENT AFTER MYOCARDIAL INFARCTION:
THE ECTIM STUDY
Marques-Vidal PI, Cambou J-P', Luc G2, Evans A E3, Arveiler D 4, Richard J L5,
Bingham A5and Cambien F6.
I MONICA Haute-Garonne, Toulouse, France; 2SERLIA - INSERM U325. Lille,
France; 3 Belfast MONICA, Northern Ireland; 4MONICA Bas-Rhin, Strasbourg,
France; 5INSERM 4258, Paris, France, 6INSERM SC7, Paris, France.
The prescriptions six months after a myocardial infarction were compared
betweenthedifferent centres ofthe ECTIMStudy (662 Patients). French patients
took significantly more medicine than Northern Irish (4.65±1.57 vs 4.17±1.57
respectively, p<0.001). French patients had a higher frequency of
hypolipidaemics, oral anticoagulants andACEinhibitors (35%vs5.5%, p<O.001;
23%vs 1.5%, p<0.001 and 18%vs5%, p<0.001, respectively), whiletheNorthern
Irish had a higherfrequency ofbeta-blockers and antiaggregating drugs (67% vs
54%, p<0.01 and 88% vs 67%, p<0.001, respectively). Three-quarters of the
patientstookanti-angina drugs (nitrates andnon-nitrates), buttheNorthern Irish
patients were almost exclusively on nitrates, while the French patients' nitrate
and non-nitrate intakes were similar.
In France, a north-to-south gradient ofthe number ofmedicines prescribed was
found (5.04±1.59 in Lille, 4.74±1.50 in Strasbourg and 4.27±1.57 in Toulouse,
p<0.001). The frequency of the prescriptions of oral anticoagulants (38%, 5%
and 15%, p<0.001), hypokalaemic diuretics (17%, 8% and 8%, p<0.01), and
antiaggregating drugs (55%, 89%and63%, p<0.001) werealsodifferentbetween
Strasbourg, Lille and Toulouse, respectively.
In conclusion, there is a lack of consensus as regards the therapy after a
myocardial infarction. A follow-up study is currently under way to assess the
outcome of the patients from each ECTIM centre.
C The Ulster Medical Society, 1993.
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CARDIOVASCULAR RISK FACTORS IN THE ECTIM STUDY
Cambou J-Pl, Arveiler D2 Evans A3, Luc G4, Marques-Vidal P', Bingham A5,
McMaster D6, Richard J L5, Ruidavets J-B ', Ducimetiere P5, and Cambien F7.
l MONICA Haute-Garonne, Toulouse, France; 2MONICA Bas-Rhin, Strasbourg,
France; 3 Belfast MONICA, Northern Ireland; 4 SERLIA-INSERM U325, Lille,
France; 5 INSERM U258, Paris, France; 6 Department of Medicine, Queen's
University of Belfast; 7 INSERM SC7, Paris, France.
The aim ofthis study isto compare patientswith myocardial infarction (category
1 MONICA) and controls. Cases and controls were born in the area of the four
MONICA centres (Belfast, Lille, Strasbourg and Toulouse).
FRANCE BELFAST
Cases Controls Cases Controls
(n=460) (n=609) (n=202) (N=202)
Previous history (%) OR* OR
- Diabetes 13.7 7.4 1.9 6.4 3.0 2.2
- High blood pressure 33.0 19.7 2.1 17.3 14.3 1.3
- Hyperlipidaemia 37.3 21.1 2.4 11.4 4.4 3.2
Tobacco
- Number of cigs 8.6 5.7 p<0.001 15.9 5.1 p<0.00O
-Smokers(%) 41.5 31.0 p<0.001 55.9 25.2 p<0.00i
Alcohol (ml/day)
- Wine 23.9 29.5 p<0.05 0.5 1.7 p<o.o5
- Beer 6.9 8.6 NS 16.4 18.2 NS
- Spirits 2.0 3.7 p<0.001 17.2 17.1 NS
- Total Alcohol 32.0 41.0 p<0.001 34.2 37.2 NS
* OR = Odds ratio
This study confirms the role ofthefourriskfactors in the incidence ofmyocardial
infarction. Alcohol and alcohol type also seems to play a part. The part that
alcohol plays in protection from atherosclerosis isclearly different in Francethan
in Belfast.
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LIPID AND LIPOPROTEIN PARAMETERS IN THE ECTIM STUDY
Parra H J', Arveiler D2, Evans A E3, Cambou J-P4, Amouyel P5, Bingham A67,
McMaster D3, Schaffer P2, Douste-Blazy Ph.4, Luc G5, RichardJ L67 7, Ducimetiere
P6, Fruchart J-C', Cambien F65.
1SERLIA - INSERMU325, Lille France; 2MONICA Bas-Rhin, Strasbourg, France;
3 Belfast MONICA, Northern Ireland; 4 MONICA Haute-Garonne, Toulouse,
France; 5 MONICA Lille, France; 6 INSERM U258, Paris, France; 7 MONICA -
Paris, France; 8 INSERM SC 7 - Paris, France.
The incidence of coronary heart disease (CHD) in middle-aged men is more
prevalent in Northern Ireland than in France. The ECTIM Study was undertaken
toinvestigatethedifferences inCHDincidence andmortality betweenthe French
populations of Strasbourg, Toulouse and Lille and the Northern Irish people in
Belfast. In the present study, an investigation oflipid parameters was performed
in normocholesterolaemic patients with myocardial infarction and controls, with
a particular emphasis on lipoprotein particles defined by their apolipoprotein
composition.
In Belfast and France, cases had lower levels of HDL-cholesterol, Apo A-I, Apo
A-Il, LpA-I and LpA:AI and higher levels of LpE:B and Lp(a):B than controls.
Triglycerides, VLDL-cholesterol, Apo B and LpCIII:B were higher in cases than
in controls only in Belfast. In controls, the levels of cholesterol fractions and
apolipoproteins were similarinthetwocountries; however, the level ofLpA-Iwas
lower and the levels ofLpE:B and Lp(a):B were higher in Belfast than in France.
A high-risk profile, characterized by a low LpAI level and by high levels ofLpE:B
and Lp(a):B, was thus more frequent in the population of Northern Ireland.
The data indicate that measurement of lipoprotein particles defined by their
apolipoprotein composition may be useful indicators ofCHD risk. However, this
profile must be assessed in prospective studies to estimate its predictive value.
© The Ulster Medical Society, 1993.
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THROMBOTIC FACTORS IN THE ECTIM STUDY: A MINI-REVIEW
Scarabin PY', Bara L2, CambouJ-P3, ArveilerD4, Luc G5, EvansA6, SamamaM2,
Cambien F7.
IINSERM U258, Paris, France; 2 Dept Hematology, Paris VI University, France;
3MONICA Haute-Garonne, Toulouse, France; 4 MONICA Bas-Rhin, Strasbourg,
France; 5 MONICA Lille, France; 6Belfast MONICA, Northern Ireland; 7 INSERM
SC7, Paris France.
Plasma levels offibrinogen, factorVIl coagulant activity (fVllc) and plasminogen
activator inhibitor type-l (PAI-1) were measured on participants in the ECTIM
study. Mean plasma fibrinogen levels were consistently and markedly higher in
casesthan incontrols, evenafteradjustmentforsmoking andotherconfounding
factors. Therewassignificantvariationin meanfibrinogen levelsbetweencentres
in the controls, with Belfast being highest (314 mg/dl) andToulouse lowest (291
mg/dl),withLilleandStrasbourg (both305mg/dl) intermediate.Thisgeographical
variation may go some way towards explaining the differences in incidence of
coronary heart disease (CHD) between Northern Ireland and France. Mean fVllc
was, in all centres, higher in controls than in cases, which does not support
previous observations from prospective studies, although different fVllc assays
have been used in different studies. In all regions except for Belfast, PAI-1 levels
were higher in controls than in patients, raising questions as to the role of PAl-
1 in CHD. Among the controls, PAl-I levels were significantly higher in the
French centresthan in Belfast, an unexpected andcurrentlyinexplicablefinding.
In conclusion, the results of the ECTIM study strengthen the epidemiological
evidence for a possible role forfibrinogen in the pathogenesis ofCHD but do not
confirm previous studies which implicated plasma fVllc and PAl-1 levels as risk
factors for CHD.
© The Ulster Medical Society, 1993.
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PARENTAL HISTORY OF MYOCARDIAL INFARCTION IN FRANCE AND
NORTHERN IRELAND
TiretLI, Kee F2, Poirier 03, NicaudVI, Evans A2, Ruidavets J-B4, Arveiler D5, Luc
G6, Bard J-M7, Fruchart J-C7, Cambien F1 3.
'INSERM U258, Paris, France; 2 Belfast MONICA, Northern Ireland; 3 INSERM
SC7 Paris, France; 4 MONICA Haute-Garonne, Toulouse, France; 5 MONICA
Bas-Rhin, Strasbourg France; 6MONICALille, France; 7SERLIA - INSERMU325,
Lille, France.
The objectives ofthe present study were to compare the prevalence of parental
history ofcoronary heart disease and its impact on individual risk ofmyocardial
infarction (MI) in Northern Ireland andFrance, andtoidentifywhichfactorscould
partly explain the familial concentration of disease. Parental history was
investigated at interviewby speciallytrainedstaff. In Belfast, data werevalidated
from General Practitioner or hospital records or death certificates, and those for
whom this validation was not possible (15%) were excluded. In France,
confidentiality legislation does not permit such validation, and self-reported
history was used. Positive parental history was morefrequent in Northern Ireland
than in France (24% vs 10% in controls' fathers, 14% vs 3% in controls' mothers).
In both countries, prevalence ofMI was higher, and mean age ofonsetwas lower,
in cases' than in controls' parents. The odds ratios for disease associated with a
premature parental MI (<60 yrs for fathers/<65 yrs for mothers) were 2.3
(p<O.OOl) in France and 2.8 (p<0.01) in Northern Ireland respectively, whereas
those associated with a late parental MI were 2.0 (p<0.001) and 1.4 (p=0.09),
respectively.
In the control populations, lipid and lipoprotein levels were compared between
individuals with and without parental history. LpAI, ApoAll, triglyceride and
Lp(a) levels did notdiffer betweenthe two groups, whereastotal cholesterol and
ApoB levels were significantly raised among those with a positive parental
history. The difference was even more marked when the parental history was
restricted to premature MI (ApoB level: 1.44 vs 1.30; p<0.01). Comparison of
genetic polymorphisms between the two groups indicated a higherfrequency of
ApoE (44+43) phenotypes among those with premature history (OR=2.4;
p=0.02). There was also an excess ofangiotensin-converting enzyme DD and ID
genotypes amongthose having a parental history, whichwaseven more marked
whenparentalhistorywasrestrictedtofatalMI (OR=2.8, p<0.01 forDD; OR=2.0,
p=0.06 for ID).
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HOW RELIABLE IS A FAMILY HISTORY OF MYOCARDIAL INFARCTION?
Kee Fl, Robo J-Y', Tiret L2, Nicaud V2, McCrum El, Evans Al, Cambien F3; for
the ECTIM Group.
'Belfast MONICA, Northern Ireland; 2 INSERM U258, Paris, France; 3INSERM
SC7 Paris, France.
Previous studies have shown that a positive family history of myocardial
infarction (MI) contributessignificantly andindependentlytoindividual risk. Less
frequently has the reliability ofself-reported family histories been assessed. Our
objective was to assess the reliability of reports of MI in first degree relatives of
Belfast ECTIM recruits.
Of the original 400 cases and controls in Belfast, 349 were interviewed
approximately 18 months to 2 years aftertheir initial recruitment. Demographic
and clinical histories were obtained in respect of 2812 first degree relatives.
Death certificates were retrieved for 753 of783 deceased relatives. The medical
history of93% ofliving first degree relatives (1893/2029) was verified primarily
through correspondence with family doctors and retrieval of hospital records.
The sensitivity of reports of MI in living first degree relatives was 72% (58/81).
The positive predictive value of such reports was 64% (58/90). For deceased
relatives reported as dying of MI the sensitivity was 66% (121/183) and the
positive predictive value was 76% (121/159). There were no differences inthese
proportions between cases andcontrols. The overall kappa scoresweremodest,
0.73 for cases and 0.65 for controls.
Whereas the odds ratio (OR) for a reported history ofMI in at least 1 parent was
1.58 (95%Confidence Intervals (CI), 1.02 to2.45), the ORfora validated history
ofMI in at least 1 parent was 1.64 (95% CI, 1.05 to 2.54). However, the OR for
a reported history ofMI among siblings was 1.75 (95% Cl, 1.02 to 2.94), slightly
greater than the OR for a validated history ofMI in these kin (1.59; 95% Cl, 0.93
to 2.72).
These results suggest that there may be some recall bias affecting self-reported
family histories ofMI among siblings inthis Belfast ECTIMsample. The relatively
modestsensitivityandpositivepredictivevaluemaylimittheoveralleffectiveness
of a targeted screening programme for risk factors for myocardial infarction
© The Ulster Medical Society,'1993.
194MONICA/ECTIMMeeting
THE IMPACT OF APOLIPOPROTEIN E POLYMORPHISM ON
LIPOPROTEINS AND RISK OF MYOCARDIAL INFARCTION;
THE ECTIM STUDY
Dallongeville J1, Luc G1, Bard J-M1, Arveiler D2, Evans A3, Cambou J-P4,
Bingham A5, Amouyel P6, Schaffer P2, Ruidavets J-B4, Cambien F7, Fruchart
J-C1, Ducimetiere P5.
'SERLIA - INSERM U325, Lille, France; 2 MONICA Bas-Rhin, Strasbourg,
France; 3BelfastMONICA, NorthernIreland;4MONICAHaute-Garonne,Toulouse,
France; 5 INSERMU258, Paris, France; 6 Institut Pasteur, Lille, France; 7INSERM
SC7, Paris, France.
In the ECTIM Study, 574 male patients aged 25-64 years were examined 3-9
months after myocardial infarction in 4 regions participating in the WHO-
MONICAProject. Controls (n=722) wererandomlyselectedfromthebackground
population. Results were adjusted for age, centre, body mass index and alcohol
consumption reported using a standardized questionnaire. The distribution of
Apo E phenotype was significantly different across the 4 control samples
(p=0.04) with a higherfrequencyofepsilon4 allele inBelfastthanToulouse. The
association ofApo E polymorphism with biological measurements was studied
in the control groups (n=644). Allelic effects were estimated from a codominant
geneticmodel. Individualscarryingtheepsilon 2allelehadlowerlevelsofplasma
chol, LDL-chol and Apo B. TG, VLDL-chol, Apo CIII, Apo E, LpCIII:B and LpE:B
levelswerehigher. Theepsilon4 allelewasassociatedwithincreasedApoBlevel
anddecreasedLpAI level. Subjectswiththeepsilon4allelehadhigherTG, VLDL-
chol, LpCIII:B levels than those having the Apo E3/3 phenotype. Relative risk
(RR) forMI associatedwithApo EphenotypesincomparisonwithApoE3/3were
found to increase in the following order: E2/2<E3/2<E3/3(RR=I)<E4/3=E4/
2<E4/4(p<0.05). The presence of the epsilon 2 and epsilon 4 alleles carried a
respective relative risk of 0.73 (p=0.05) and 1.33 (p=0.02) in a codominant
model logistic model. In conclusion, Apo E polymorphisms explain a modest
proportion of myocardial infarction in the ECTIM Study.
C The Ulster Medical Society, 1993.
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APOLIPOPROTEIN B POLYMORPHISMS IN THE ECTIM STUDY
Visvikis S, for the ECTIM group.
Centre de Medecine Preventive (URA CNR 597), 2 avenue du Doyen Jacques
Parisot, 54500 Vandoeuvre-les-Nancy, France
The aim of the ECTIM study is to identify genetic factors involved in the
development of myocardial infarction (MI). More than 600 patients with MI and
700 controls were recruited from 4 populations, in France (Lille, Strasbourg,
Toulouse) and Northern Ireland (Belfast). Several lipid variables including LDL-
cholesterol, Apo B and polymorphisms ofthe Apo B gene including the EcoRI,
MspI, XbaI, signal peptide (SIPE) and3'HVRwereinvestigated inall participants.
Homozygotes and heterozygotes for the 48 repeats allele (HVR48+) were more
frequent in cases (21.8%) than incontrols (15.0%) (p<0.003 afteradjustmenton
population). Nostatisticallysignificantheterogeneity ofthisassociationcouldbe
detectedacrosspopulations. Thepopulationadjustedodds-ratio(95%confidence
interval) forMI was 1.55 (1.15-2.07) and the fraction ofcases attributable to the
HVR48+ genotypewas 0.074. Body mass index (BMI) was positively associated
with MI in HVR48+ individuals (p<0.004) but not in HVR48- individuals. In
HVR48+ individuals, the mean excess weight (standardized to a height of
1.75 m) in cases relative to controls was: 6.6 kg in Belfast, 6.3 kg in Lille, 2.5 kg
in Strasbourg and 2.3 kg in Toulouse. In individuals with a BMI>26 kg/M2 (the
median ofBMI in controls), the population adjusted odds-ratio forMl associated
with the HVR48+ genotype was 2.21 (1.47-3.31) (p<0.0001) andthe fraction of
cases attributable to the HVR48+ genotype was 0.14. In contrast, in individuals
with a BMI<=26 kg/m2, the HVR48+ genotype was unrelated to MI.
In Belfast, in addition to the HVR48 polymorphism the SIPE polymorphism was
also associatedwithMI. Significantassociationswere alsoobserved between the
Apo B signal peptide polymorphism and mean levels of total cholesterol, LDL
cholesterol, ApoB and Lp(a) in the Strasbourg control population. Individuals
homozygous for the rare allele had higher levels of these lipid parameters. In
Belfast, although not statistically significant, the Apo B signal peptide
polymorphism had a similar effect on Apo-B-related parameters as seen in
Strasbourg. NosignificantassociationswereobservedintheToulousepopulation
where the risk of MI is three times lower than in Belfast.
Finally, the polymorphisms investigated in the ECTIM study were in strong
linkage disequilibrium and these disequilibria were of similar magnitude in the
fourpopulations. These last results suggestthat inthe presence ofoneofseveral
variants of the Apo B gene carried by the HVR48 allele, overweight has a
deleterious impact on lipid metabolism and raises the risk of MI.
© The Ulster Medical Society, 1993.
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(CA)n REPEAT POLYMORPHISM OF THE APOLIPOPROTEIN All GENE:
RESEARCH OF ASSOCIATION WITH MYOCARDIAL INFARCTION AND
LIPOPROTEIN LEVELS: THE ECTIM STUDY
Amouyel PI, Brousseau T1, Vidal 01, Cambou J-p2, Luc GI, Evans A3, Arveiler
D4, Fruchart J-C1, Cambien F5.
l Institut Pasteur, Lille, France; 2MONICA Haute-Garonne, Toulouse, France;
3 BelfastMONICA, Northern Ireland;4 MONICA Bas-Rhin, Strasbourg; 5INSERM
SC7, Paris, France.
Apolipoprotein All (ApoAII) isthe second major High Density Lipoprotein (HDL)
component with apolipoprotein Al. In a multicentre retrospective study of
myocardialinfarction, the ECTIMstudy, weexploredtheassociationofanApoAII
gene polymorphism with coronary heart disease and with lipid and lipoprotein
plasma levels. We studied a (CA)n repeat length polymorphism located in intron
2 of the gene. The ECTIM study was carried out in four regions: Belfast area,
Toulouse area, Strasbourg area and Lille area. A sample of men aged between
25 and 64 was recruited: cases of myocardial infarction were included and
controls were selected from the general population as age matched controls for
myocardial infarction cases. The (CA)n repeat genotypes were detected with
PCR amplification technique in 1358 subjects (595 cases and 763 controls). We
identified 10 different alleles. The effect of this polymorphism on lipids and
lipoproteins was analysed in the control group for subjects without any
hypolipidaemic drugs.
22 2X XX p
ApoAIl(mg/dl) 33 (8) 35 (8) 37 (8) 0.0001
HDL Chol.(mg/dl) 52 (15) 51(15) 52 (15) NS
LDL Chol. (mg/dl) 146 (33) 150 (39) 159 (42) 0.007
Allele 2thusappearedtobeassociatedwithApoAll plasma levelsandinfluenced
the levels of LDL-Cholesterol plasma levels, but not HDL-Cholesterol plasma
levels. However, no association of this allele 2 with the disease was observed.
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(TTA)n REPEAT POLYMORPHISM OF THE HMG CoA REDUCTASE GENE:
RESEARCH OF ASSOCIATION WITH MYOCARDIAL INFARCTION AND
LIPOPROTEIN LEVELS: THE ECTIM STUDY
Brousseau T', Amouyel PI, Vidal 0, Cambou J_P2, Luc G', Evans A3, Arveiler
D4, Fruchart J-C1, Cambien F5.
I Institut Pasteur, Lille, France; 2 MONICA Haute-Garonne, Toulouse, France;
3 Belfast MONICA, Northern Ireland; 4 MONICA Bas-Rhin, Strasbourg, France;
5INSERM SC7, Paris France.
HMG CoAreductase isa keyenzymeintheinitialstepsofcholesterol metabolism.
Regulation of the rate of cholesterol biosynthesis is, in general, mediated by
regulation of HMG CoA reductase activity. In a multicentre retrospective study
ofmyocardial infarction, TheECTIMstudy, weexploredthe associationofa HMG
CoA reductase gene polymorphism with coronary heart disease and with lipid
and lipoprotein plasma levels. We studied a (TTA)n repeatlength polymorphism
located 10 kbp3' ofexon 2ofthegene. TheECTIMstudywascarriedoutbetween
1988 and 1992 in four regions: Belfast (Northern Ireland), Toulouse (South of
France), Strasbourg (North-East of France) and Lille (North of France). A
sample of men aged between 25 and 64 was recruited: cases of myocardial
infarction were included and controls were selected from the general population
as age matched controls for myocardial infarction cases. The (TTA)n repeat
genotypes were detected with PCR amplification technique in 1297 subjects
(558 cases and 739 controls). We identified eight different alleles ranging from
10 to 17 repeats. The presence of at least one 15 repeat allele was significantly
less frequent (p<0.008) in cases (14.7%) than in controls (20.4%). The effect of
this polymorphism on lipid and lipoprotein levels was analysed in the control
group for subjects without any hypolipidaemic drugs. The presence of at least
one 15 repeat allele was associated with high levels of low density lipoprotein
cholesterol (p<0.003). HMG CoA reductase genepolymorphismthusappears to
be associated with the atherosclerotic process and coronary heart disease.
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LIPOPROTEIN LIPASE GENE POLYMORPHISMS:
ASSOCIATIONS WITH MYOCARDIAL INFARCTION AND LIPOPROTEIN
LEVELS IN THE ECTIM STUDY
Fumeron F1, Jemaa RI, Poirier 02, Lecerf L2, Evans A3, Arveiler D4, Luc G5,
Cambou J-P6, Bard J-M5, Fruchart J-C5, Apfelbaum MI, Cambien F2.
1 INSERM U258 and2 INSERM SC7, Paris, France; 3 Belfast MONICA, Northern
Ireland;4MONICA Bas-Rhin, Strasbourg, France; 5SERLIAInstitut Pasteur, Lille,
France; 6MONICA Haute-Garonne, Toulouse, France.
Lipoprotein lipase (LPL) is a major determinant ofthe hydrolysis oftriglyceride
rich lipoproteins. Four DNA polymorphisms of the LPL gene were examined
(Pvull, Hindlll, Asn291 ->Ser and Ser447->stop) to detect associations with
lipidandlipoproteinlevels andwiththeoccurrenceofmyocardial infarction inthe
ECTIM study.
Significant pairwise linkage disequilibria were found between Pvull, Hindlll and
Ser447->stop polymorphisms. Asn291->Ser was in linkage disequilibrium
with Pvull only.
Lipid related variables were analysed in the control group to avoid the bias
resulting from lifestyle (treatment) changes after myocardial infarction. Hindill
polymorphism was associated with apolipoprotein (Apo) C-Ill levels (p=0.04).
Triglyceride, Apo B, ApoCIII and LpE-B levels wereweakly associated with Pvull
polymorphism (0.05 <p<0.10). Ser447->stop polymorphism was associated
with triglyceride and Apo C-Ill levels (p=0.04 and p=0.02 respectively). No
association between Asn291->Ser polymorphism and lipid related variables
was detected.
HindlllandPvullpolymorphismsweresignificantly associatedwiththeoccurrence
of myocardial infarction, independently from their effects on triglycerides
(p=0.015 and p=0.006 respectively, after adjustment on centre and triglyceride
levels by multiple logistic regression). The relative risk of myocardial infarction
(estimated bytheoddsratio) forH2H2subjectswas 1.8whencomparedto H1H1
(homozygotesforHindillpolymorphism). Therelative riskforP2P2was 1.4when
compared to PlP1 subjects (homozygotes for PvuII polymorphism). Moreover
there was an interaction effect between Pvull polymorphism and triglyceride
levels on myocardial infarction: triglycerides were associated with myocardial
infarction only in PIPI group (p=0.006).
These results indicate an effect ofthe genetic variation(s) of LPL on myocardial
infarction. This could be due to the central role ofLPL in lipoprotein metabolism,
includingthepost-prandialphase, andnotonlytoaneffectonfastinglipoproteins.
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GENETIC VARIATION AT THE B FIBRINOGEN LOCUS IN RELATION TO
PLASMA FIBRINOGEN CONCENTRATIONS AND RISK OF MYOCARDIAL
INFARCTION
Scarabin PY1, Bara L2, Ricard S3, Poirier 03, Cambou J-P4, Arveiler D5, Luc G6,
Evans A7, Samama M2, Cambien F3.
1 INSERMU258, Paris, France; 2ParisVIUniversity, France; 3INSERMSC7, Paris,
France; 4 MONICA Haute-Garonne, Toulouse, France; 5 MONICA Bas-Rhin,
Strasbourg, France,6MONICALille, France; 7BelfastMONICA, NorthernIreland.
Increased plasma fibrinogen concentration is a majorcardiovascular riskfactor.
Conflicting results on genetic variations in plasma fibrinogen levels have been
reported. Furthermore, whether fibrinogen genotype is associated with the risk
of ischaemic heart disease has not been studied so far. An HaeIII restriction
fragment length polymorphism (RFLP) of the B-fibrinogen gene was used in a
case-control study to investigate the genetic variation at this locus in relation to
plasma fibrinogen concentrations andthe riskofmyocardial infarction (MI). Five
hundred and thirty-three male patients and 648 control subjects were recruited
from 4 WHO MONICA centres in Northern Ireland and in France. The absence
ofHaellI cutting site (H2allele) wasassociatedwithasignificantriseinfibrinogen
concentrationsinbothpatientsandcontrols. TheeffectoftheHaeIIIpolymorphism
onplasmafibrinogenlevelsdidnotsignificantly differbetweencentres. Fibrinogen
levels were higher in smokers than in non-smokers. The difference between the
two groups was larger in subjects with the genotype H2H2 than in those with the
genotype H1H1 or H1H2, regardless ofthe case-control status. However, there
was nosignificant interaction between smoking statusandgenotypeinitseffects
onfibrinogen levels. HaelIl genotype accountedforabout 1%ofthetotalvariance
in fibrinogen levels, whereas smoking and age together explained 7% and 5% in
controls and patients, respectively. The frequency of the H2 allele was 0.21 in
controls and 0.19 in patients. The estimate ofrelative risk forMI associated with
thepresenceoftheH2allelewas0.89 (95%confidenceinterval: 0.69 - 1.13).The
results were consistent with respect to the centres. Multiple regression analysis
showed that smoking and raised plasma fibrinogen made independent
contributions to the increase in MI risk. There was no significant interaction
between HaelIl genotypeandtheeffectofsmokingonMl risk. These data provide
furtherevidence for a role ofthe genetic variation atthe8-fibrinogen locus inthe
determination ofplasmafibrinogen concentrations. However, thisstudyfailed to
detect an association between this genetic variation and the MI risk. Further
investigations are needed to assess the relative contribution of genetic and
environmental determinants of plasma fibrinogen to the prediction of
atherothrombotic diseases.
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FACTOR VII GENOTYPE DETERMINES FACTOR VII COAGULANT
ACTIVITY IN THE ECTIM STUDY
Green F1, Lane A1, Humphries SI, Scarabin PY2, Bara L3, Cambou J-P4, Arveiler
D5, Luc G6, Evans A7, Cambien F8.
I Dept Medicine, UCL Medical School, London; 2INSERM U258, Paris, France;
3 Dept Hematology, Paris VI University, France; 4 MONICA Haute-Garonne,
Toulouse, France; 5 MONICA Bas-Rhin, Strasbourg, France; 6 MONICA Lille,
France; 7 Belfast MONICA, Northern Ireland; 8 INSERM SC7, Paris France.
Raised plasma level of factor VII coagulant activity (fVIIc) has been implicated
as a risk factor for myocardial infarction (MI) and so genetic factors determining
anindividual's fVllc level mayinfluence riskofMl. Wehave, therefore, genotyped
individuals taking part in the ECTIM study for the Arg/GIn353 polymorphism of
thefactorVII gene. This polymorphism has previously been shown to be strongly
associated with plasma fVIlc. This was confirmed in the ECTIM study, where the
G1nallelewas associatedwithsignificantly lowerfVIIc levelsinbothMI cases and
controls in all centres, withthe exception ofLillecontrolswhere a similarbutnon-
significant trend was observed. Among the MI cases, the mean fVIIc level in the
Arg/Arghomozygotes was 1 15%ofstandard, intheheterozygotes was 102%and
in the Gln/Gln homozygotes was 78%, with p<0.0001 (by ANOVA). The
corresponding values for the controls (excluding those on oral anticoagulants
(OACs) andthosewith coronary heartdisease (CHD)) were, respectively, 1 18%,
104% and 91%, with p<0.0001. The frequency of the Gln allele did not differ
significantly between centres or between cases and controls, with the frequency
in the controls (excluding CHDs and those on OACs) being 0.12 (95% Cl
0.10-0.14) and in the MI cases being 0.11 (0.08-0.12). This suggests that the
factor VIl Arg/G1n353 polymorphism may not be a strong determinant of risk of
MI despite its effect on fVllc levels. A previous study had suggested that the
correlation of plasma fVllc and triglyceride levels may be stronger in Arg/Arg
homozygotes than in G1n allele carriers, however, this was not confirmed in the
ECTIM study, with the possible exception ofthe Belfast sample which showed a
similar trend.
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ASSOCIATION BETWEEN VARIATION IN THE PROMOTER REGION OF
THE PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) GENE AND
PLASMA PA1-1 ACTIVITY: THE ECTIM STUDY
YeS', GreenFRI, HenneyAM', DawsonSJ', HumphriesSE', ScarabinPY2, Evans
A3, Cambou J-P4, Arveiler D5, Bara L6, Cambien F7.
1 Division ofCardiovascular Genetics, Department ofMedicine, Rayne Institute,
UCL Medical School, London, UK; 2 INSERM U258, Paris, France; 3 Belfast
MONICA, Northern Ireland; 4 MONICA Haute-Garonne, Toulouse, France;
5MONICABas-Rhin, Strasbourg, France;6DeptHaematology, ParisVIUniversity,
France; 7 INSERM SC7, Paris, France.
We have studied the association ofa common insertion/deletion polymorphism
in the plasminogen activator inhibitor-1 (PAl-1) gene promoter with plasma
levels of PAl-1 activity in 474 patients with myocardial infarction and 638
matched controls from the four centres participating in the ECTIM study. In the
Belfastsamples PAl-1 levelswerehigherin patientsthancontrols (8.0%p<0.05),
while in the three French centres levels were higher in the controls than in the
patients. The frequency of the deletion allele (4G) was similar in patients and
controls (0.57 and 0.55 respectively) and it was associated with elevated levels
of plasma PAl-1 in both groups. The effect of genotype on PAl-1 levels was
consistent in all regions and was greater in patients than controls, but was
statistically significantonlyinthe patientsfromBelfastandStrasbourg and inthe
patient sample as a whole (p<0.05). After adjusting for differences between
centres, body mass index and plasma triglycerides, which affect levels ofPAl-1,
patients and controls homozygous for the 4G allele had mean PAl-1 activities,
respectively, 17.6% and 6.5% higher than 5G homozygotes, with heterozygotes
having intermediate values. In both patients and controls from Belfast there was
a positive correlation between plasmafibrinogen levelsandPAl-1 activities in4G
homozygotes (r=0.23 p=0.06, r=0.24 p=0.08 respectively), while in those with
other genotypes this correlation was negative. This relationship was observed
only weakly inthe patients and controlsfromthe French centres. These data are
consistent with a previous study showing a differential effect of cytokines on
transcription fromthetwoalleles inHepG2cells, andconfirmthatvariation atthe
PAl-1 locus contributes to inter-individual differences in plasma PAl-I levels,
especially during the acutephase. This suggests thatthispolymorphism maybe
one of the genetic factors that determines an individual's risk of thrombotic
disease.
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ACE INSERTION/DELETION POLYMORPHISM: A NEW RISK FACTOR
FOR MYOCARDIAL INFARCTION?
Soubrier F', Poirier 02, Lecerf L2, Cambien F2, Evans A3, Cambou J-P4, Arveiler
D5, Luc G6, Tiret L7.
I INSERMU36, Paris, France; 2 INSERM SC7, Paris, France; 3 Belfast MONICA,
Northern Ireland; 4MONICA Haute-Garonne, Toulouse, France; 5 MONICA Bas-
Rhin, Strasbourg, France; 7 INSERM U258, Paris France.
About 25% ofthe variability ofplasma ACE level is associated with an Insertion
(1)/Deletion (D) polymorphism of the ACE gene which is a marker for an
unknownfunctionalvariantsituatedwithinorclosetotheACEgene.Asachronic
exposure to high ACE levels may modulate the activity of peptides involved in
vasoconstriction and smooth muscle cell proliferation and predispose to
myocardial infarction (MI), we considered that the ACE gene could be a
candidateforMI. Totestthis possibility, thefrequency oftheACE I/D genotypes
was compared in patients with MI (n=610) and controls (n=733) participating in
the ECTIM study in Belfast, Lille, Strasbourg and Toulouse. The DD genotype
was more frequent in patients than in controls, especially in those considered to
be at low risk (plasma Apo B<1.25 g/l and BMI<26 kg/M2). In this subgroup
which represented 13% ofthe patients, the relative risk ofMI associated with the
DD genotype was approximately 3 and the attributable risk was 30%. In control
subjects, parental history of fatal MI was associated with a significantly higher
frequency ofthe D allele in Belfast as well as in France. These results which will
have to be confirmed in other studies and other populations suggest that the
ACE/ID polymorphism is a new potent risk factor for MI.
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ECTIM AND FUTURE STUDIES IN BELFAST
Kee Fl, Tiret L2, Weston J E', Bard J-M3, Evans A El, McCrum E E', Cambien
F4, Fruchart J-C3, Luc G5, McMaster D6.
I Belfast MONICA, Northern Ireland; 2 INSERM U258 Paris; 3 SERLIA - INSERM
U325, Lille, France;4INSERMSC7, Paris, France; 5Institut Pasteur, Lille, France;
6 Department of Medicine, Queen's University of Belfast, Northern Ireland.
Some caution is appropriate before the results from ECTIM to date are more
widely generalised. Ongoing MONICA registration and the ECTIM Family study
in Belfast may allow someofthis reservation to be addressed in extensions ofthe
protocol.
i In particular, ECTIM cases were recruited within nine months ofsurviving
a myocardial infarction. The fact that some alleles (such as the ACE
insertion/deletion polymorphism) seemto confer greater risk to surviving
patients with an otherwise low risk profile suggests that these alleles may
be implicated in fatalMI in patients with other established risk factors. It
is thus intended that post-mortem tissue from subjects dying early in the
course of MI is retrieved (n=200), DNA recovered from the archived
material and the frequency of "susceptibility" genotypes determined.
ii Although the incidence ofischaemic heart disease in men is substantially
greaterthan inwomen, coronaryheartdisease isoneofthemostcommon
causes ofdeath in both sexes. Though there is epidemiological evidence
indicating a gradient of risk to women from "traditional" risk factors such
as smoking, hypertension or raised serum cholesterol, the attributable
risks are often found to be somewhat smaller than in men. The Belfast
ECTIM extension will recruit 200 female cases and 200 female controls.
This will allow a comparison with the findings in Belfast men on the
importance of the lipoparticle profiles and specific genetic determinants
of risk. This may point to the need for further studies in other centres.
iii A natural extension of the study of population associations between
genotypes and disease is to discover whether the "susceptibility" alleles
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BELFAST HYPERLIPIDAEMIA STUDY
EvansAE', Nicholls PD2, McMasterD3, O'KaneM2, Cambien F4, KeeFl, McCrum
E El.
I Belfast MONICA, Northern Ireland; 2The lipid clinic, Royal Victoria Hospital,
Belfast, Northern Ireland; 3 Department of Medicine, Queen's University of
Belfast, Northern Ireland; 4 Inserm SC7, Paris, France.
It is well established that when LDL receptors are deficient, LDL cholesterol
accumulates and coronary risk is greatly increased. Similarly, it is known that
certain variantsofapolipoprotein B 100 (egwhenthereisa mutation inthecodon
for the amino acid 3500) result in poor binding between the apolipoprotein and
the LDL receptor with cholesteryl ester-enriched LDL particles consequently
accumulating in the plasma. The 3500 polymorphism was rare in the ECTIM
Study. The Belfast Hyperlipidaemia Study will investigate those types of
Fredericksonhyperlipoproteinaemiaswhich areassociatedwithincreasedlevels
of apolipoprotein B 100, mainly (Type IIA, IIB and IV) in relation to several
polymorphisms ofthe apolipoprotein B gene. Twohundredpreviously untreated
patients will be recruited from the lipid clinic of the Royal Victoria Hospital,
Belfast. Male patients aged 40-64 years and female patients aged 50-64 years
will be eligible. All should have types IIA, IIB or IV hyperlipoproteinaemia and
both of their parents should have been born in the historical entity of Ulster.
Twenty mls of blood will be drawn at EDTA after a full overnight fast.
Polymorphisms ofthe apolipoprotein B gene of special interest are (1) variants
already published: Apo B/Xbal, EcoRI, signal peptide, 3500, 4311 biallelic
polymorphism; Apo B 3'HVR (2) new variants of the apolipoprotein B gene
identified in the ECTIM Study and (3) other polymorphisms. Biochemical
estimations will be carried out in the Department of Medicine, The Queen's
University of Belfast and the apolipoprotein B and other polymorphisms are to
be investigated at INSERM SC7, Paris. It is estimated that the study will take 18
months - 2 years to complete.
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THE PRIME STUDY
Evans A El, Richard J L2, McMaster D3, Cambien F4, McCrum E E', Sykes D5,
Bingham A2, Bard J-M6, Kee Fl, Fruchart J-C6, Arveiler D7, Shaffer P7, Amouyel
P8, Luc G8, Scarabin p y2, Ducimetiere P2, Cambou J-P9, Douste-Blazy Ph9,
Ruidavets J-B9, Gey F'0, Juhan I"I, Aillaud M F, Perret B9, McConville M',Yarnell
J W G1.
'Belfast MONICA, NorthernIreland;2INSERMU258, Paris, France;3Department
Medicine, Queen's University ofBelfast, Northern Ireland; 4 INSERM SC7, Paris,
France; 5 Department of Psychology, Queen's University of Belfast, Northern
Ireland;6SERLIA, INSERMU325, Lille, France;7MONICABas-Rhin, Strasbourg,
France; 8 Institut Pasteur, Lille, France; 9 MONICA Haute-Garonne, Toulouse,
France; 10 Vitamin Unit, Berne Switzerland; 11 Laboratoire d'Hematologie,
Marseille, France.
The PRIME Study is a prospective study of the determinants of coronary heart
disease incidence and mortality in 50-59 yearold males in theMONICA Centres
inFranceandNorthern Ireland. TheStudyisbuildingonthefindingsoftheECTIM
Study. The four centres provide a stark contrast in ischaemic heart disease
incidence with rates in Belfast four times those in Toulouse and more tha-n three
times those in Lille and Strasbourg. Subjects are drawn from General Practice,
Health Check-up Centres and Industry in the four centres and are screened after
a full overnight fast. Total intake to the study will be close to 1 1,000 and already
approximately8,500subjectshavebeenrecruited. Screeningbeganinmid 1991
and will be completed later this year and thereafter 5-7 year follow-up will take
place. The high-risk lipid profile, i.e. low LPA1 and high LPE:B and LP(a)
observed in Belfast will receive special attention and these factors will be
measured in fresh plasma from each subject. The environmental factors of
special interest are diet (in particular fatty acids and the major antioxidant
vitamins A, E and C). Alcohol consumption with special reference to type of
beverage and amount and pattern of drinking, physical activity, cigarette
consumption, drug intake, psychosocial factors including shift work and family
histories are also being investigated. Gene environment interactions are of key
interest, especially inrelationtopolymorphismsoftheapolipoprotein Bgeneand
the DD polymorphism of the ACE gene. The study will also look at other lipid
parameters, thrombotic factors and hormones.
POSTSCRIPT
After the meeting Dr Pierre Ducimetiere unveiled a plaque at 7 Marcus Square, Newry to
commemorate DrSamuel Black, thepioneerCardiologistwholivedtherefrom 1819 - 1832. DrBlack
was first to notice the large disparity in heart disease between the north of Ireland and France. The
plaque was erected by the Ulster History Circle with the generous assistance of Newry and Mourne
District Council.
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